Brain+ A/S

No longer operating

Copenhagen, Hovedstaden, DenmarkFounded 201211–50 employeesbrain-plus.comLinkedIn

Ayla is a UK digital health company helping care homes deliver evidence-based cognitive care for people living with dementia. Its Class I UKCA-marked medical device supports NICE-recommended Cognitive Stimulation Therapy, ongoing cognitive wellbeing and outcome measurement.

Visit brain-plus.com ↗

Founded: 2012
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

Recent highlights

Brain+ moved further from product development toward commercial deployment during 2025. On Apr 3, 2025, it expanded its Ayla contract with Copenhagen Municipality to nine elderly daycare centers, describing it as its largest sales contract at that point. On Apr 16, 2025, Devika Wood was appointed CEO, replacing founder Kim Baden-Kristensen as the company adopted a more commercial focus. Brain+ then signed a second UK sales agreement with Park Homes UK Group on May 26, 2025, initially covering four care homes with potential expansion to 21. On May 28, 2025, dementia-care authority Antony Hall joined as a strategic advisor, while Vishal Shah was elected to the board at the 2025 Annual General Meeting on May 30, 2025. The strongest disclosed commercial expansion came on Sep 16, 2025, when Agincare Homes agreed to deploy Ayla at Gainsborough Care Home, with a pathway to as many as 31 homes and an annual multi-site contract value of approximately £31,000.

Market position

Brain+ operates in the digital therapeutics and dementia-care software segment, with a focus narrower than general cognitive-training applications. Its principal commercial product, Ayla, supports structured group-based Cognitive Stimulation Therapy for people with mild to moderate dementia and is described as a Class I UKCA-marked medical device supporting NICE-recommended care. That combination of clinical workflow, care-home implementation, and outcome tracking gives Brain+ a differentiated proposition versus consumer brain-training apps, which generally do not target institutional dementia care or provide care-team reporting. The company is also extending beyond a single seven-week intervention through maintenance and everyday cognitive-wellbeing programmes. Commercial evidence includes contracts with Syddjurs Municipality, Copenhagen Municipality, Park Homes UK Group, and Agincare Homes. Its competitive position therefore appears to depend more on clinical validation, regulatory status, implementation support, and care-home distribution than on scale or broad consumer reach.

Growth & opportunities

Brain+ shows a gradual transition from grant-supported product development to contract-led commercialization. Its disclosed financing totals $523,194, including a $516,050 grant announced on Dec 14, 2023, a $7,144 grant announced on Sep 20, 2023, and an earlier 2014 Venture Round with no disclosed amount. The operating inflection point was the development and launch of Ayla, which Brain+ introduced in Denmark and the UK in 2024 as a certified medical device for dementia care. Commercial momentum strengthened in late 2024 and 2025: Syddjurs Municipality signed a three-year Ayla contract on Dec 5, 2024; Copenhagen Municipality expanded access to nine daycare centers on Apr 3, 2025; and UK agreements followed with Park Homes UK Group on May 26, 2025 and Agincare Homes on Sep 16, 2025. The appointment of Devika Wood as CEO on Apr 16, 2025 formalized the commercial shift. Growth remains early-stage: public information does not provide revenue, customer counts, retention, deployment volumes, or employee-growth figures, so the trajectory is evidenced primarily by contract expansion rather than financial scale.

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

What makes Brain+ A/S distinct

reccy insights

What makes Brain+ A/S distinct

01Extends cognitive care beyond an initial intervention through structured maintenance and everyday cognitive wellbeing.
02Enables care teams to deliver evidence-based Cognitive Stimulation Therapy consistently within care homes.
03Provides outcomes that help teams understand what is working and improve care over time.
04Combines dementia care expertise, clinical knowledge, technology and implementation support.
05Works alongside care teams and residents to design solutions that are practical in real-world care settings.

Technology & products2

Technology & products

Ayla – your CST Assistant
A digital platform providing structured Cognitive Stimulation Therapy sessions to support group therapy for people with mild to moderate dementia.
Recover
A smartphone application featuring cognitive training games and tools designed to help users improve mental performance.

Class I UKCA-marked medical device supporting the delivery of NICE-recommended Cognitive Stimulation Therapy.
Structured cognitive care programmes with outcome tracking.
Digital support for ongoing cognitive wellbeing and maintenance after the initial seven-week CST programme.

Recent updates12

Launches, partnerships and team changes from press coverage

Sep 16, 2025Partnership
Brain+ signed a new agreement with Agincare Homes to deploy its Ayla CST Assistant at Gainsborough Care Home, with a pathway to scale across up to 31 homes and an annual multi-site contract value of about £31,000.
tradingview.com
May 30, 2025Team change
Vishal Shah, previously a board observer and advisor, was elected as a new board member of Brain+ A/S during the 2025 Annual General Meeting. Tim Jürgens was re-elected as Chairman, and all other existing board members were re-elected.
news.cision.com
May 28, 2025Team change
Antony Hall, a UK dementia-care authority, joined Brain+ as a strategic advisor.
news.cision.com
May 26, 2025Partnership
Brain+ has signed its second UK sales agreement with Park Homes UK Group to deploy its Ayla digital Cognitive Stimulation Therapy assistant in four care homes, with the potential to expand to all 21 care homes in the group, marking a strategic partnership in the UK dementia care sector.
news.cision.com
Apr 3, 2025Partnership
Brain+ A/S and Copenhagen Municipality have signed an extended and expanded contract for Ayla, a CST Assistant, to cover nine elderly daycare centers. This contract represents the largest sales contract for Brain+ to date and is a positive step towards a potential multi-year, multi-site contract.
news.cision.com
Mar 21, 2025Team change
Vishal Shah, a UK care sector expert, joined Brain+ as a new Board Observer and advisor, bringing insights into the UK care sector.
news.cision.com
Mar 11, 2025Team change
Vishal Shah, a UK care sector expert, joined Brain+ as an advisor and board observer.
news.cision.com
Jan 1, 2025Team change
Brain+ appointed HC Andersen Capital as its new Certified Advisor, effective Jan 1, 2025.
news.cision.com
Dec 31, 2024Product launch
Brain+ launched Ayla - your CST Assistant, a certified medical device for dementia care, in Denmark and the UK in 2024.
tradingview.com
Dec 31, 2024Team change
Devika Wood was appointed CEO of Brain+, replacing founder Kim Baden-Kristensen as the company shifted to a commercial focus.
tradingview.com
Dec 5, 2024Partnership
Brain+ secures a 3-year sales contract with Syddjurs Municipality for Ayla CST Assistant, marking a major milestone.
tradingview.com
Jan 1, 2024Product launch
Ayla is a CST Assistant designed to support group-based Cognitive Stimulation Therapy for people with dementia.
news.cision.com

Show all 12 updates

About Brain+ A/S

Products: Ayla – your CST Assistant, Recover
Leadership: Devika Wood, Chief Executive OfficerUlrik Ditlev Eriksen, Co-founder & Chief Product Officer
Focus areas: Digital health, medical device, dementia care, cognitive stimulation therapy, healthcare, care homes, clinical outcomes, cognitive wellbeing
Headquarters: Copenhagen, Hovedstaden, Denmark
Founded: 2012
Employees: 11–50
Status: No longer operating
Trademarks: 1